Recommendations and guidelines from Sweden
| Source | Drugs and therapeutics committee county council of Skåne5 | The National Board of Health and Welfare6 |
|---|---|---|
| 1. Can we trust it? | Yes, probably | Yes |
| a. Is up to date? | 2014 | 2012 |
| b. Is the content based on best available evidences? | Based on The National Board of Health and Welfare systematic review and other updated references | Systematic review |
| c. Is the process for the preparation fully described and transparent? | No clear description of the working process. Expert group prepare background for decision, committee including chairs of all expert groups | Detailed description on who did what and what sources. Drafts communicated nationally before final guidelines |
| d. Are important experts, users and customers involved? | Permanent group of five regional specialists; physicians and pharmacist. | 15–20 selected national experts in areas including clinical, communication, health economy etc. Patient involvement not stated. |
| e. Is conflicts of interest (COI) declared and taken account of? | Declared COI. If COI does not participate in the decision | All Swedish agencies have common rules for COI. |
| 2. Can we use it? | Yes, see below | Yes, but time consuming, see below |
| a. Is it easy to read, understand and apply? | 14 pages (in Swedish), recommendations given | 116 pages(in Swedish), evidence tabulated and prioritised (1–10, 1 highest) |
| b. Does it give us information to improve patient care? | Background for risk assessment, recommendations for treatment and follow-up, questions and answers. | List actions and priorities based on EBM levels for the population as a base for patient individualisation |
| What should we recommend based on the case? | Alendronate or risedronate | Alendronate, zoledronate injection if swallowing problems (priority 2) |